Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy Planning, Computer-Assisted | 119 | 2024 | 1659 | 16.100 |
Why?
|
Monte Carlo Method | 125 | 2024 | 1256 | 14.040 |
Why?
|
Relative Biological Effectiveness | 60 | 2022 | 312 | 10.760 |
Why?
|
Radiotherapy, Intensity-Modulated | 40 | 2024 | 800 | 8.990 |
Why?
|
Protons | 55 | 2023 | 1112 | 7.320 |
Why?
|
Radiotherapy Dosage | 115 | 2024 | 2895 | 7.110 |
Why?
|
Radiometry | 52 | 2024 | 813 | 6.990 |
Why?
|
Organs at Risk | 30 | 2023 | 358 | 6.730 |
Why?
|
Linear Energy Transfer | 37 | 2021 | 152 | 6.640 |
Why?
|
Photons | 28 | 2024 | 581 | 4.330 |
Why?
|
Neoplasms, Radiation-Induced | 15 | 2024 | 547 | 3.570 |
Why?
|
Neutrons | 12 | 2024 | 77 | 3.540 |
Why?
|
Phantoms, Imaging | 45 | 2024 | 2509 | 3.060 |
Why?
|
Neoplasms, Second Primary | 13 | 2020 | 1051 | 2.870 |
Why?
|
Scattering, Radiation | 25 | 2020 | 488 | 2.830 |
Why?
|
Uncertainty | 23 | 2023 | 750 | 2.770 |
Why?
|
Radiation Dosage | 30 | 2023 | 1957 | 2.690 |
Why?
|
Radiotherapy, Conformal | 12 | 2021 | 549 | 2.600 |
Why?
|
Models, Biological | 33 | 2024 | 9460 | 2.180 |
Why?
|
Radiation Injuries | 14 | 2024 | 1184 | 2.090 |
Why?
|
Radiotherapy | 18 | 2024 | 1498 | 2.060 |
Why?
|
Radiobiology | 8 | 2020 | 89 | 1.920 |
Why?
|
Radiation Oncology | 11 | 2024 | 559 | 1.910 |
Why?
|
Models, Theoretical | 20 | 2021 | 3560 | 1.900 |
Why?
|
Neoplasms | 42 | 2024 | 21990 | 1.870 |
Why?
|
Movement | 12 | 2019 | 1474 | 1.860 |
Why?
|
Algorithms | 44 | 2024 | 13952 | 1.770 |
Why?
|
Head and Neck Neoplasms | 19 | 2024 | 2882 | 1.750 |
Why?
|
Radiotherapy, High-Energy | 9 | 2015 | 228 | 1.730 |
Why?
|
Lung Neoplasms | 27 | 2023 | 13267 | 1.590 |
Why?
|
Radiotherapy, Computer-Assisted | 7 | 2015 | 90 | 1.550 |
Why?
|
Ependymoma | 5 | 2018 | 320 | 1.530 |
Why?
|
Dose-Response Relationship, Radiation | 21 | 2018 | 882 | 1.520 |
Why?
|
Lymphopenia | 4 | 2023 | 280 | 1.300 |
Why?
|
Necrosis | 4 | 2024 | 1605 | 1.290 |
Why?
|
Positron-Emission Tomography | 21 | 2017 | 6457 | 1.220 |
Why?
|
Liver Neoplasms | 12 | 2023 | 4313 | 1.080 |
Why?
|
Respiration | 9 | 2015 | 1654 | 1.070 |
Why?
|
Computer Simulation | 31 | 2024 | 6198 | 1.060 |
Why?
|
Metal Nanoparticles | 6 | 2021 | 397 | 1.010 |
Why?
|
Prostatic Neoplasms | 18 | 2022 | 11075 | 0.990 |
Why?
|
Radiation Monitoring | 3 | 2015 | 103 | 0.960 |
Why?
|
Brain Neoplasms | 14 | 2024 | 8981 | 0.950 |
Why?
|
DNA Damage | 12 | 2023 | 2439 | 0.900 |
Why?
|
Tomography, X-Ray Computed | 28 | 2024 | 20499 | 0.880 |
Why?
|
Four-Dimensional Computed Tomography | 4 | 2020 | 141 | 0.870 |
Why?
|
Software | 13 | 2023 | 4416 | 0.870 |
Why?
|
Humans | 217 | 2024 | 757650 | 0.860 |
Why?
|
Electrons | 8 | 2018 | 264 | 0.830 |
Why?
|
Models, Statistical | 18 | 2024 | 5068 | 0.810 |
Why?
|
Radiation Pneumonitis | 2 | 2020 | 102 | 0.810 |
Why?
|
Radiation Tolerance | 9 | 2021 | 480 | 0.810 |
Why?
|
Infratentorial Neoplasms | 3 | 2018 | 98 | 0.800 |
Why?
|
Microtechnology | 2 | 2019 | 70 | 0.790 |
Why?
|
DNA Repair | 10 | 2023 | 2038 | 0.790 |
Why?
|
Lung | 13 | 2021 | 9979 | 0.770 |
Why?
|
Brain Stem | 5 | 2018 | 857 | 0.760 |
Why?
|
Elementary Particles | 3 | 2010 | 52 | 0.750 |
Why?
|
Artifacts | 6 | 2024 | 1894 | 0.730 |
Why?
|
Nanofibers | 1 | 2021 | 66 | 0.730 |
Why?
|
Metals | 4 | 2024 | 717 | 0.720 |
Why?
|
Water | 12 | 2021 | 1402 | 0.710 |
Why?
|
Cell Survival | 15 | 2019 | 5782 | 0.710 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 5272 | 0.640 |
Why?
|
Motion | 5 | 2015 | 779 | 0.630 |
Why?
|
Rib Fractures | 1 | 2020 | 128 | 0.630 |
Why?
|
Radiation Protection | 6 | 2016 | 424 | 0.620 |
Why?
|
Radiosurgery | 5 | 2019 | 1341 | 0.610 |
Why?
|
Arteriovenous Malformations | 2 | 2019 | 397 | 0.570 |
Why?
|
Carcinoma, Hepatocellular | 4 | 2023 | 2293 | 0.550 |
Why?
|
Skull Base Neoplasms | 2 | 2017 | 269 | 0.540 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2020 | 471 | 0.500 |
Why?
|
Reproducibility of Results | 24 | 2024 | 20039 | 0.480 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 584 | 0.480 |
Why?
|
Gamma Rays | 3 | 2017 | 317 | 0.480 |
Why?
|
Lymphocytes | 5 | 2023 | 2611 | 0.470 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 506 | 0.460 |
Why?
|
Gold | 5 | 2021 | 479 | 0.460 |
Why?
|
Equipment Failure Analysis | 3 | 2010 | 842 | 0.450 |
Why?
|
Prostate | 2 | 2022 | 1761 | 0.440 |
Why?
|
Prostheses and Implants | 4 | 2019 | 1270 | 0.440 |
Why?
|
Particle Accelerators | 4 | 2024 | 174 | 0.430 |
Why?
|
Medulloblastoma | 6 | 2017 | 678 | 0.430 |
Why?
|
Calibration | 5 | 2018 | 813 | 0.430 |
Why?
|
Physics | 3 | 2021 | 90 | 0.420 |
Why?
|
Cerebellar Neoplasms | 5 | 2017 | 586 | 0.410 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1088 | 0.410 |
Why?
|
Chordoma | 5 | 2016 | 346 | 0.410 |
Why?
|
Spine | 4 | 2017 | 1111 | 0.400 |
Why?
|
Models, Chemical | 2 | 2016 | 610 | 0.390 |
Why?
|
Radiation, Ionizing | 4 | 2022 | 251 | 0.370 |
Why?
|
Seminoma | 1 | 2012 | 134 | 0.370 |
Why?
|
DNA Breaks, Double-Stranded | 6 | 2023 | 607 | 0.360 |
Why?
|
Carbon | 4 | 2022 | 667 | 0.350 |
Why?
|
Radiation-Sensitizing Agents | 4 | 2016 | 346 | 0.350 |
Why?
|
Breast Neoplasms | 5 | 2020 | 20999 | 0.340 |
Why?
|
Tumor Burden | 5 | 2018 | 1887 | 0.340 |
Why?
|
Risk Assessment | 11 | 2024 | 23819 | 0.330 |
Why?
|
Heart | 2 | 2021 | 4382 | 0.330 |
Why?
|
Probability | 5 | 2023 | 2461 | 0.330 |
Why?
|
Nanoparticles | 1 | 2021 | 1940 | 0.330 |
Why?
|
DNA | 5 | 2022 | 7199 | 0.330 |
Why?
|
Nasopharyngeal Neoplasms | 5 | 2021 | 287 | 0.320 |
Why?
|
Sensitivity and Specificity | 14 | 2017 | 14638 | 0.320 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2024 | 8945 | 0.320 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2007 | 1214 | 0.320 |
Why?
|
Rectum | 4 | 2017 | 891 | 0.310 |
Why?
|
Fetus | 1 | 2015 | 1860 | 0.310 |
Why?
|
Radioisotopes | 2 | 2023 | 495 | 0.310 |
Why?
|
Male | 49 | 2024 | 358227 | 0.300 |
Why?
|
Whole-Body Counting | 1 | 2008 | 36 | 0.300 |
Why?
|
Statistics as Topic | 1 | 2014 | 2357 | 0.300 |
Why?
|
Alpha Particles | 2 | 2021 | 29 | 0.290 |
Why?
|
Cyclotrons | 2 | 2004 | 30 | 0.280 |
Why?
|
Equipment Design | 5 | 2010 | 3501 | 0.280 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1415 | 0.270 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2796 | 0.270 |
Why?
|
Eye Neoplasms | 4 | 2012 | 306 | 0.260 |
Why?
|
Cricetinae | 6 | 2015 | 2426 | 0.260 |
Why?
|
Testicular Neoplasms | 1 | 2012 | 794 | 0.260 |
Why?
|
Respiratory Mechanics | 1 | 2009 | 699 | 0.250 |
Why?
|
Cell Line | 9 | 2015 | 15594 | 0.240 |
Why?
|
Stochastic Processes | 2 | 2023 | 354 | 0.240 |
Why?
|
Mathematical Concepts | 1 | 2024 | 73 | 0.240 |
Why?
|
Brain | 8 | 2024 | 26950 | 0.230 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 850 | 0.220 |
Why?
|
Quality Assurance, Health Care | 3 | 2014 | 2167 | 0.220 |
Why?
|
Retrospective Studies | 13 | 2023 | 79982 | 0.220 |
Why?
|
Polyethylene | 2 | 2011 | 186 | 0.220 |
Why?
|
Microspheres | 2 | 2023 | 787 | 0.220 |
Why?
|
Time Factors | 17 | 2024 | 39815 | 0.210 |
Why?
|
Feasibility Studies | 9 | 2017 | 5195 | 0.200 |
Why?
|
Health Care Costs | 1 | 2015 | 3234 | 0.200 |
Why?
|
Cell Line, Tumor | 7 | 2021 | 16891 | 0.200 |
Why?
|
Fibrosarcoma | 1 | 2003 | 308 | 0.190 |
Why?
|
Hemodynamics | 2 | 2023 | 4156 | 0.190 |
Why?
|
Radiography | 5 | 2015 | 6957 | 0.190 |
Why?
|
Yttrium Radioisotopes | 1 | 2021 | 107 | 0.180 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2018 | 295 | 0.180 |
Why?
|
Spiral Cone-Beam Computed Tomography | 1 | 2020 | 34 | 0.180 |
Why?
|
Female | 31 | 2024 | 389985 | 0.180 |
Why?
|
Organ Specificity | 3 | 2014 | 1955 | 0.170 |
Why?
|
DNA, Neoplasm | 1 | 2005 | 1745 | 0.170 |
Why?
|
Endpoint Determination | 2 | 2020 | 590 | 0.170 |
Why?
|
Child, Preschool | 11 | 2017 | 42044 | 0.170 |
Why?
|
Whole-Body Irradiation | 2 | 2014 | 433 | 0.170 |
Why?
|
Workflow | 1 | 2024 | 850 | 0.170 |
Why?
|
Linear Models | 3 | 2016 | 5857 | 0.160 |
Why?
|
Copper | 2 | 2011 | 366 | 0.160 |
Why?
|
Cricetulus | 3 | 2015 | 815 | 0.160 |
Why?
|
Plastics | 2 | 2017 | 115 | 0.160 |
Why?
|
Pulse Radiolysis | 1 | 2018 | 6 | 0.160 |
Why?
|
Biology | 1 | 2021 | 289 | 0.160 |
Why?
|
Bayes Theorem | 2 | 2024 | 2320 | 0.160 |
Why?
|
Cell Growth Processes | 1 | 2019 | 384 | 0.160 |
Why?
|
Child | 15 | 2018 | 79787 | 0.150 |
Why?
|
Animals | 22 | 2024 | 167777 | 0.150 |
Why?
|
Lymphocyte Count | 1 | 2020 | 778 | 0.150 |
Why?
|
Antineoplastic Agents | 2 | 2019 | 13603 | 0.140 |
Why?
|
Cell Physiological Phenomena | 1 | 2018 | 150 | 0.140 |
Why?
|
Diagnostic Imaging | 3 | 2021 | 3524 | 0.140 |
Why?
|
Spinal Neoplasms | 3 | 2014 | 714 | 0.140 |
Why?
|
ROC Curve | 1 | 2024 | 3562 | 0.140 |
Why?
|
Adolescent | 14 | 2019 | 87832 | 0.140 |
Why?
|
Knowledge Bases | 1 | 2017 | 97 | 0.140 |
Why?
|
Adult | 16 | 2024 | 219747 | 0.130 |
Why?
|
Germanium | 1 | 2016 | 7 | 0.130 |
Why?
|
Optic Chiasm | 1 | 2016 | 91 | 0.130 |
Why?
|
Pancreatic Neoplasms | 2 | 2013 | 5348 | 0.130 |
Why?
|
Drug Carriers | 1 | 2021 | 705 | 0.130 |
Why?
|
Thoracic Wall | 1 | 2018 | 199 | 0.130 |
Why?
|
Paclitaxel | 2 | 2021 | 1731 | 0.130 |
Why?
|
Age Factors | 6 | 2017 | 18328 | 0.130 |
Why?
|
Macromolecular Substances | 1 | 2018 | 1433 | 0.130 |
Why?
|
Recombinases | 1 | 2016 | 66 | 0.130 |
Why?
|
Infant | 7 | 2017 | 36043 | 0.130 |
Why?
|
Research Report | 1 | 2019 | 367 | 0.130 |
Why?
|
Oxygen Radioisotopes | 1 | 2015 | 75 | 0.130 |
Why?
|
Computer Graphics | 2 | 2019 | 340 | 0.130 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 7982 | 0.130 |
Why?
|
Normal Distribution | 1 | 2015 | 272 | 0.120 |
Why?
|
Reference Values | 3 | 2015 | 4918 | 0.120 |
Why?
|
Tumor Cells, Cultured | 4 | 2005 | 6128 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5254 | 0.120 |
Why?
|
Patient Positioning | 2 | 2014 | 326 | 0.120 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2015 | 146 | 0.120 |
Why?
|
Cobalt Radioisotopes | 3 | 2016 | 75 | 0.120 |
Why?
|
Body Height | 2 | 2012 | 1567 | 0.120 |
Why?
|
Neovascularization, Pathologic | 1 | 2024 | 2638 | 0.120 |
Why?
|
Pelvic Neoplasms | 1 | 2015 | 247 | 0.110 |
Why?
|
Ions | 3 | 2022 | 256 | 0.110 |
Why?
|
Thoracic Neoplasms | 1 | 2015 | 265 | 0.110 |
Why?
|
CHO Cells | 3 | 2013 | 1389 | 0.110 |
Why?
|
Radiopharmaceuticals | 1 | 2023 | 2634 | 0.110 |
Why?
|
Temporal Lobe | 1 | 2021 | 1688 | 0.110 |
Why?
|
Cytosol | 1 | 2016 | 886 | 0.110 |
Why?
|
Endonucleases | 1 | 2016 | 369 | 0.110 |
Why?
|
Optic Nerve | 1 | 2016 | 567 | 0.110 |
Why?
|
Cranial Irradiation | 1 | 2015 | 390 | 0.100 |
Why?
|
Optic Nerve Glioma | 1 | 2012 | 32 | 0.100 |
Why?
|
Pelvis | 1 | 2017 | 732 | 0.100 |
Why?
|
Fiducial Markers | 1 | 2013 | 132 | 0.100 |
Why?
|
Urinary Bladder | 2 | 2016 | 1151 | 0.100 |
Why?
|
Adenocarcinoma | 1 | 2009 | 6325 | 0.100 |
Why?
|
Physical Phenomena | 2 | 2018 | 48 | 0.100 |
Why?
|
Breast | 1 | 2020 | 1961 | 0.100 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3839 | 0.100 |
Why?
|
Subtraction Technique | 3 | 2009 | 510 | 0.100 |
Why?
|
Cell Nucleus | 2 | 2020 | 2905 | 0.100 |
Why?
|
Aged | 8 | 2024 | 167889 | 0.090 |
Why?
|
Cohort Studies | 5 | 2018 | 41198 | 0.090 |
Why?
|
Meningioma | 2 | 2016 | 1217 | 0.090 |
Why?
|
Occupational Exposure | 2 | 2014 | 1810 | 0.090 |
Why?
|
Gadolinium | 1 | 2016 | 959 | 0.090 |
Why?
|
Calorimetry | 1 | 2010 | 129 | 0.090 |
Why?
|
Meningeal Neoplasms | 2 | 2016 | 1247 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 4 | 2021 | 36271 | 0.090 |
Why?
|
Alopecia | 1 | 2014 | 411 | 0.090 |
Why?
|
Computers | 1 | 2012 | 596 | 0.090 |
Why?
|
Blood Vessels | 1 | 2015 | 1112 | 0.080 |
Why?
|
Software Validation | 1 | 2009 | 59 | 0.080 |
Why?
|
Liver | 3 | 2022 | 7503 | 0.080 |
Why?
|
Drug Delivery Systems | 1 | 2021 | 2211 | 0.080 |
Why?
|
Risk | 3 | 2018 | 9590 | 0.080 |
Why?
|
Neoplasms, Experimental | 1 | 2014 | 1228 | 0.080 |
Why?
|
Aging | 1 | 2008 | 8650 | 0.080 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2008 | 39 | 0.080 |
Why?
|
Dental Implants | 1 | 2017 | 791 | 0.080 |
Why?
|
Benchmarking | 2 | 2015 | 1042 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2015 | 1147 | 0.080 |
Why?
|
Body Burden | 1 | 2008 | 158 | 0.080 |
Why?
|
X-Rays | 2 | 2017 | 307 | 0.080 |
Why?
|
Sphenoid Sinus | 1 | 2008 | 99 | 0.080 |
Why?
|
Whole Body Imaging | 1 | 2010 | 278 | 0.070 |
Why?
|
Middle Aged | 10 | 2024 | 219219 | 0.070 |
Why?
|
Neuroectodermal Tumors | 1 | 2007 | 22 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2015 | 916 | 0.070 |
Why?
|
Spinal Cord | 1 | 2015 | 1815 | 0.070 |
Why?
|
Nuclear Warfare | 1 | 2007 | 30 | 0.070 |
Why?
|
Thorax | 1 | 2010 | 553 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2012 | 1788 | 0.070 |
Why?
|
Mutation | 4 | 2019 | 29928 | 0.070 |
Why?
|
Longevity | 1 | 2014 | 1050 | 0.070 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2017 | 1404 | 0.070 |
Why?
|
Chromosome Aberrations | 3 | 2020 | 1764 | 0.070 |
Why?
|
Therapy, Computer-Assisted | 1 | 2008 | 266 | 0.070 |
Why?
|
Haplorhini | 1 | 2007 | 529 | 0.070 |
Why?
|
Spinal Cord Neoplasms | 1 | 2008 | 262 | 0.070 |
Why?
|
Magnetics | 1 | 2008 | 600 | 0.060 |
Why?
|
Mice | 8 | 2016 | 81107 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 9245 | 0.060 |
Why?
|
Data Interpretation, Statistical | 2 | 2018 | 2687 | 0.060 |
Why?
|
Rad51 Recombinase | 2 | 2016 | 188 | 0.060 |
Why?
|
Risk Factors | 4 | 2022 | 73716 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7366 | 0.060 |
Why?
|
Pituitary Neoplasms | 2 | 2016 | 1313 | 0.060 |
Why?
|
Primates | 1 | 2007 | 523 | 0.060 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2007 | 3338 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 5639 | 0.060 |
Why?
|
Lethal Dose 50 | 1 | 2003 | 72 | 0.060 |
Why?
|
Boron Neutron Capture Therapy | 1 | 2003 | 50 | 0.060 |
Why?
|
Astrocytoma | 1 | 2008 | 775 | 0.060 |
Why?
|
Mitochondria | 1 | 2016 | 3584 | 0.050 |
Why?
|
Fanconi Anemia | 2 | 2016 | 324 | 0.050 |
Why?
|
Tumor Stem Cell Assay | 1 | 2002 | 115 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2016 | 3864 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2020 | 58559 | 0.050 |
Why?
|
Incidence | 4 | 2018 | 21217 | 0.050 |
Why?
|
Helium | 1 | 2022 | 119 | 0.050 |
Why?
|
Dogs | 1 | 2007 | 3838 | 0.050 |
Why?
|
Neoplasm Staging | 2 | 2017 | 11083 | 0.050 |
Why?
|
Smoking | 1 | 2018 | 9036 | 0.050 |
Why?
|
Patient Selection | 1 | 2013 | 4235 | 0.050 |
Why?
|
Palliative Care | 1 | 2016 | 3568 | 0.050 |
Why?
|
Quality Improvement | 1 | 2016 | 3793 | 0.050 |
Why?
|
Swine | 1 | 2011 | 5892 | 0.050 |
Why?
|
Body Weight | 1 | 2012 | 4602 | 0.050 |
Why?
|
Fibroblasts | 2 | 2020 | 4087 | 0.050 |
Why?
|
Leukemia P388 | 1 | 2000 | 14 | 0.050 |
Why?
|
Clinical Competence | 1 | 2016 | 4760 | 0.050 |
Why?
|
Macaca mulatta | 1 | 2007 | 2316 | 0.040 |
Why?
|
Visible Human Projects | 1 | 2019 | 12 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 326 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2015 | 10750 | 0.040 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 4902 | 0.040 |
Why?
|
Bone Marrow | 1 | 2010 | 2910 | 0.040 |
Why?
|
Young Adult | 8 | 2021 | 58764 | 0.040 |
Why?
|
Laboratories | 1 | 2003 | 460 | 0.040 |
Why?
|
Actuarial Analysis | 1 | 2019 | 374 | 0.040 |
Why?
|
Blood Cells | 1 | 2021 | 305 | 0.040 |
Why?
|
Biophysical Phenomena | 1 | 2000 | 320 | 0.040 |
Why?
|
Inflammation | 1 | 2019 | 10718 | 0.040 |
Why?
|
Cataract Extraction | 1 | 2003 | 465 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 628 | 0.040 |
Why?
|
Prognosis | 2 | 2017 | 29493 | 0.040 |
Why?
|
Biophysics | 1 | 2000 | 380 | 0.040 |
Why?
|
Apoptosis | 1 | 2015 | 9469 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 9574 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6469 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39018 | 0.040 |
Why?
|
Chemical Phenomena | 1 | 2018 | 508 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2019 | 442 | 0.040 |
Why?
|
Texas | 1 | 2018 | 402 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2007 | 2824 | 0.030 |
Why?
|
Florida | 1 | 2018 | 428 | 0.030 |
Why?
|
United States | 4 | 2018 | 71907 | 0.030 |
Why?
|
Cesium Radioisotopes | 1 | 2016 | 38 | 0.030 |
Why?
|
Vinblastine | 1 | 2017 | 488 | 0.030 |
Why?
|
Rhabdoid Tumor | 1 | 2017 | 210 | 0.030 |
Why?
|
Carboplatin | 1 | 2018 | 792 | 0.030 |
Why?
|
Growth Plate | 1 | 2017 | 274 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 419 | 0.030 |
Why?
|
Biochemical Phenomena | 1 | 2015 | 58 | 0.030 |
Why?
|
Endodeoxyribonucleases | 1 | 2016 | 164 | 0.030 |
Why?
|
Thyroid Neoplasms | 1 | 2008 | 2326 | 0.030 |
Why?
|
Penis | 1 | 2016 | 212 | 0.030 |
Why?
|
Jurkat Cells | 1 | 2016 | 735 | 0.030 |
Why?
|
Teratoma | 1 | 2017 | 402 | 0.030 |
Why?
|
Sex Factors | 1 | 2008 | 10497 | 0.030 |
Why?
|
Self-Assessment | 1 | 2016 | 393 | 0.030 |
Why?
|
Rats | 1 | 2010 | 23681 | 0.030 |
Why?
|
Survival Rate | 1 | 2008 | 12685 | 0.030 |
Why?
|
Embolization, Therapeutic | 1 | 2023 | 1406 | 0.030 |
Why?
|
Melanoma | 1 | 2012 | 5690 | 0.030 |
Why?
|
Pregnancy | 1 | 2015 | 29720 | 0.030 |
Why?
|
Thigh | 1 | 2015 | 241 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 3480 | 0.030 |
Why?
|
Phthalazines | 1 | 2016 | 382 | 0.030 |
Why?
|
Nucleic Acid Conformation | 1 | 2016 | 895 | 0.030 |
Why?
|
Permeability | 1 | 2015 | 718 | 0.030 |
Why?
|
Neuroma, Acoustic | 1 | 2016 | 459 | 0.030 |
Why?
|
Rotation | 1 | 2014 | 514 | 0.030 |
Why?
|
User-Computer Interface | 1 | 2019 | 1397 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2017 | 2922 | 0.020 |
Why?
|
Automation | 1 | 2014 | 581 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2012 | 26173 | 0.020 |
Why?
|
Plasmids | 1 | 2016 | 2275 | 0.020 |
Why?
|
Cisplatin | 1 | 2017 | 1647 | 0.020 |
Why?
|
Particle Size | 1 | 2015 | 1641 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2016 | 824 | 0.020 |
Why?
|
Thermal Conductivity | 1 | 2010 | 16 | 0.020 |
Why?
|
Esophagus | 1 | 2017 | 1023 | 0.020 |
Why?
|
Intestine, Small | 1 | 2017 | 1205 | 0.020 |
Why?
|
Fast Neutrons | 1 | 2010 | 18 | 0.020 |
Why?
|
Thyroid Gland | 1 | 2017 | 1167 | 0.020 |
Why?
|
Skin | 1 | 2003 | 4464 | 0.020 |
Why?
|
Carcinoma | 1 | 2021 | 2330 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2015 | 977 | 0.020 |
Why?
|
Air | 1 | 2009 | 186 | 0.020 |
Why?
|
Histones | 1 | 2019 | 2577 | 0.020 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2011 | 262 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 2010 | 286 | 0.020 |
Why?
|
Rabbits | 1 | 2015 | 4771 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2913 | 0.020 |
Why?
|
Sacrum | 1 | 2010 | 276 | 0.020 |
Why?
|
Cerebellum | 1 | 2015 | 1497 | 0.020 |
Why?
|
Treatment Failure | 1 | 2014 | 2636 | 0.020 |
Why?
|
Models, Molecular | 1 | 2016 | 5411 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 2646 | 0.020 |
Why?
|
Adenoma | 1 | 2016 | 2147 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4641 | 0.020 |
Why?
|
Transfection | 1 | 2013 | 5779 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5864 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2511 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 3757 | 0.020 |
Why?
|
Cell Communication | 1 | 2012 | 1651 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8815 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10416 | 0.010 |
Why?
|
Research Design | 1 | 2020 | 6151 | 0.010 |
Why?
|
Societies, Medical | 1 | 2016 | 3887 | 0.010 |
Why?
|
Glioblastoma | 1 | 2019 | 3480 | 0.010 |
Why?
|
Bone and Bones | 1 | 2014 | 2559 | 0.010 |
Why?
|
Cause of Death | 1 | 2014 | 3668 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13464 | 0.010 |
Why?
|
Recurrence | 1 | 2014 | 8426 | 0.010 |
Why?
|
Kidney | 1 | 2017 | 7013 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2021 | 64242 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11709 | 0.010 |
Why?
|